膀胱癌生物标志物的临床状态模型
Clinical states model for biomarkers in bladder cancer.
作者信息
Apolo Andrea B, Milowsky Matthew, Bajorin Dean F
机构信息
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
出版信息
Future Oncol. 2009 Sep;5(7):977-92. doi: 10.2217/fon.09.57.
Abstract
Bladder cancer is a significant healthcare problem in the USA, with a high recurrence rate, the need for expensive continuous surveillance and limited treatment options for patients with advanced disease. Research has contributed to an understanding of the molecular pathways involved in the development and progression of bladder cancer, and that understanding has led to the discovery of potentially diagnostic, predictive and prognostic biomarkers. In this review, a clinical states model of bladder cancer is introduced and integrated into a paradigm for biomarker development. Biomarkers are systematically incorporated with predefined end points to aid in clinical management.
摘要
在美国，膀胱癌是一个重大的医疗保健问题，其复发率高，需要进行昂贵的持续监测，且晚期疾病患者的治疗选择有限。研究有助于人们了解膀胱癌发生和发展过程中涉及的分子途径，而这种了解又促成了潜在的诊断、预测和预后生物标志物的发现。在本综述中，引入了一种膀胱癌临床状态模型，并将其整合到生物标志物开发的范例中。生物标志物被系统地与预先定义的终点相结合，以辅助临床管理。
相似文献
1
Clinical states model for biomarkers in bladder cancer.膀胱癌生物标志物的临床状态模型
Future Oncol. 2009 Sep;5(7):977-92. doi: 10.2217/fon.09.57.
2
An online tool for evaluating diagnostic and prognostic gene expression biomarkers in bladder cancer.一种用于评估膀胱癌诊断和预后基因表达生物标志物的在线工具。
BMC Urol. 2015 Jul 1;15:59. doi: 10.1186/s12894-015-0056-z.
3
Bladder cancer biomarkers: review and update.膀胱癌生物标志物：综述与更新
Asian Pac J Cancer Prev. 2014;15(6):2395-403. doi: 10.7314/apjcp.2014.15.6.2395.
4
Molecular markers in bladder cancer.膀胱癌的分子标志物。
World J Urol. 2019 Jan;37(1):31-40. doi: 10.1007/s00345-018-2503-4. Epub 2018 Sep 26.
5
Immunohistochemistry Biomarkers in Nonmuscle Invasive Bladder Cancer.非肌层浸润性膀胱癌中的免疫组化生物标志物
Appl Immunohistochem Mol Morphol. 2017 Mar;25(3):178-183. doi: 10.1097/PAI.0000000000000280.
6
Considerations on the use of diagnostic markers in management of patients with bladder cancer.关于诊断标志物在膀胱癌患者管理中的应用的思考。
World J Urol. 2008 Feb;26(1):39-44. doi: 10.1007/s00345-007-0232-1. Epub 2007 Dec 19.
7
Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification.非肌层浸润性膀胱癌进展的分子生物标志物——超越传统风险分层
Nat Rev Urol. 2025 Feb;22(2):75-91. doi: 10.1038/s41585-024-00914-7. Epub 2024 Aug 2.
8
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature.膀胱癌的预后和预测工具：文献综述。
Eur Urol. 2015 Aug;68(2):238-53. doi: 10.1016/j.eururo.2015.01.032. Epub 2015 Feb 21.
9
Bladder cancer biomarker discovery using global metabolomic profiling of urine.利用尿液的整体代谢组学分析发现膀胱癌生物标志物。
PLoS One. 2014 Dec 26;9(12):e115870. doi: 10.1371/journal.pone.0115870. eCollection 2014.
10
Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?膀胱尿路上皮癌的分子标志物：我们是否已经达成目标？
Nat Rev Urol. 2011 Dec 13;9(1):41-51. doi: 10.1038/nrurol.2011.193.
引用本文的文献
1
The multifaceted roles of mucins family in lung cancer: from prognostic biomarkers to promising targets.黏蛋白家族在肺癌中的多方面作用：从预后生物标志物到有前景的靶点。
Front Immunol. 2025 Jun 27;16:1608140. doi: 10.3389/fimmu.2025.1608140. eCollection 2025.
2
Extracellular vesicles-a new player in the development of urinary bladder cancer.细胞外囊泡——膀胱癌发展中的新角色。
Ther Adv Med Oncol. 2025 Jan 23;17:17588359241297529. doi: 10.1177/17588359241297529. eCollection 2025.
3
Insights from animal models of bladder cancer: recent advances, challenges, and opportunities.膀胱癌动物模型的见解：最新进展、挑战与机遇
Oncotarget. 2017 May 9;8(34):57766-57781. doi: 10.18632/oncotarget.17714. eCollection 2017 Aug 22.
4
Immunological basis in the pathogenesis and treatment of bladder cancer.膀胱癌发病机制及治疗中的免疫学基础。
Expert Rev Clin Immunol. 2015 Feb;11(2):265-79. doi: 10.1586/1744666X.2015.983082. Epub 2014 Nov 13.
5
Multimodal management of muscle-invasive bladder cancer.肌层浸润性膀胱癌的多模式管理
Curr Probl Cancer. 2014 May-Jun;38(3):80-108. doi: 10.1016/j.currproblcancer.2014.06.001. Epub 2014 Jun 23.
6
A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness.一项定量蛋白质组学分析揭示了 CUL3 在膀胱癌侵袭性中的相关性。
PLoS One. 2013;8(1):e53328. doi: 10.1371/journal.pone.0053328. Epub 2013 Jan 8.
7
Molecular expression profiling with respect to KEGG hsa05219 pathway.关于KEGG hsa05219通路的分子表达谱分析。
Ecancermedicalscience. 2011;5:189. doi: 10.3332/ecancer.2011.189. Epub 2011 Feb 22.
本文引用的文献
1
Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients.肺癌患者富集循环肿瘤细胞检测的临床意义初步研究。
J Thorac Oncol. 2009 Jan;4(1):30-6. doi: 10.1097/JTO.0b013e3181914125.
2
Biomarkers in oncology drug development: rescuers or troublemakers?肿瘤学药物研发中的生物标志物：救星还是麻烦制造者？
Expert Opin Drug Metab Toxicol. 2008 Nov;4(11):1391-402. doi: 10.1517/17425255.4.11.1391.
3
E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.膀胱移行细胞癌患者中E-钙黏蛋白的组织表达及尿中可溶性E-钙黏蛋白形式
Urol Int. 2008;81(3):320-4. doi: 10.1159/000151412. Epub 2008 Oct 16.
4
Detection of circulating tumor cells in patients with urothelial cancer.尿路上皮癌患者循环肿瘤细胞的检测
Ann Oncol. 2009 Feb;20(2):305-8. doi: 10.1093/annonc/mdn627. Epub 2008 Oct 3.
5
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.循环肿瘤细胞可预测转移性去势抵抗性前列腺癌患者从治疗中获得的生存益处。
Clin Cancer Res. 2008 Oct 1;14(19):6302-9. doi: 10.1158/1078-0432.CCR-08-0872.
6
A microRNA expression ratio defining the invasive phenotype in bladder tumors.一种定义膀胱癌侵袭表型的 microRNA 表达比率。
Urol Oncol. 2010 Jan-Feb;28(1):39-48. doi: 10.1016/j.urolonc.2008.06.006. Epub 2008 Sep 16.
7
A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.微卫星和甲基化尿液分析在预测尿路上皮细胞癌复发方面的性能比较以及通过贝叶斯网络分析确定一组标志物
BJU Int. 2008 Jun;101(11):1448-53. doi: 10.1111/j.1464-410X.2008.07591.x. Epub 2008 Mar 4.
8
Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells.对表皮生长因子受体抑制剂的敏感性要求尿路上皮癌细胞中E-钙黏蛋白的表达。
Clin Cancer Res. 2008 Mar 1;14(5):1478-86. doi: 10.1158/1078-0432.CCR-07-1593.
9
Resistance to therapy caused by intragenic deletion in BRCA2.由BRCA2基因内缺失导致的治疗耐药性。
Nature. 2008 Feb 28;451(7182):1111-5. doi: 10.1038/nature06548. Epub 2008 Feb 10.
10
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.继发性突变作为BRCA2突变癌症中顺铂耐药的一种机制。
Nature. 2008 Feb 28;451(7182):1116-20. doi: 10.1038/nature06633. Epub 2008 Feb 10.
Zotero 插件